Investing.com - Financial Markets Worldwide

Qyuns Therapeutics Co Ltd (2509ta)

Hong Kong
Currency in HKD
22.12
-0.52(-2.30%)
Closed·
2509ta Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Unusual trading volume
2509ta is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
20.8824.26
52 wk Range
5.9530.95
Key Statistics
Edit
Prev. Close
-
Open
23.6
Day's Range
20.88-24.26
52 wk Range
5.95-30.95
Volume
1.31M
Average Volume (3m)
304.89K
1-Year Change
13.2%
Book Value / Share
1.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2509ta Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 10
Significant return over the last week
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Qyuns Therapeutics Co Ltd Company Profile

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which is in Phase III clinical trial for the treatment of prurigo nodularis. The company also commercializes QX001S, which is an IL-12/L-23p49 inhibitor for psoriasis under the SAILEXIN brand. In addition, it develops, manufactures, and commercializes QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD; QX004N, an IL-23p19 inhibitor in Phase II clinical trial to treat psoriasis and Crohn’s disease; QX013N, a humanized IgG1 mAb targeting c-kit; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial for the treatment of systemic lupus erythematosus; QX007N, a humanized IgG1 mAb targeting IL-33 for the treatment of moderate-to-severe COPD and asthma; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
339
Market
Hong Kong

Compare 2509ta to Peers and Sector

Metrics to compare
2509ta
Peers
Sector
Relationship
P/E Ratio
−13.7x−20.3x−0.5x
PEG Ratio
−0.360.360.00
Price/Book
20.1x6.3x2.6x
Price / LTM Sales
29.0x14.6x3.3x
Upside (Analyst Target)
-−1.8%43.5%
Fair Value Upside
Unlock−6.5%6.9%Unlock

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-0.74 / --
Revenue / Forecast
113.87M / --
EPS Revisions
a
a
Unlock
Last 90 days

2509ta Income Statement

FAQ

What Stock Exchange Does Qyuns Therapeutics Trade On?

Qyuns Therapeutics is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Qyuns Therapeutics?

The stock symbol for Qyuns Therapeutics is "2509ta."

What Is the Qyuns Therapeutics Market Cap?

As of today, Qyuns Therapeutics market cap is 4.91B.

What Is Qyuns Therapeutics's Earnings Per Share (TTM)?

The Qyuns Therapeutics EPS (TTM) is -1.53.

From a Technical Analysis Perspective, Is 2509ta a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Qyuns Therapeutics Stock Split?

Qyuns Therapeutics has split 0 times.

How Many Employees Does Qyuns Therapeutics Have?

Qyuns Therapeutics has 339 employees.

What is the current trading status of Qyuns Therapeutics (2509ta)?

As of 07 Aug 2025, Qyuns Therapeutics (2509ta) is trading at a price of 22.12, with a previous close of 0.00. The stock has fluctuated within a day range of 20.88 to 24.26, while its 52-week range spans from 5.95 to 30.95.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.